Introduction

Stem Cell research act as a panacea for sequelae after stroke and has been extensively investigated as one of the most promising treatment door [1,2]. Great optimism has resulted from bone marrow-derived stem cells (BMSC) ever since the reestablishment of functionality of injured organs was postulated successfully [3]. Mononuclear stem cells (MNC) have experimented ethically but none of the reports could yield a statistically significant difference in the outcome measures in stroke [4,5].

These cells are capable of producing broad-spectrum cytokines, chemokines, growth factors, and ECM molecules [6,7]. The secreted factors promote cell proliferation and cytoprotection through the production of antioxidants and anti-apoptotic molecules [8]. Two of the most prominent growth factors; brain derived neurotrophic growth factor (BDNF) & vascular endothelial growth factor (VEGF) promote neuronal differentiation, synaptic plasticity, and axonal sprouting enhancing sensorimotor recovery [9].

Imaging technologies are essential for stem cell tracking in-vivo in both experimental and clinical studies. Functional MRI (fMRI) acts as a bio surrogate marker that measures neural activity for studying functional improvement post stroke [10]. The fMRI response can be evoked by direct modulation of the nervous system using physical therapy, pharmacological agents, sensory stimuli like artificial intelligence, cognitive tasks, and the very recent cell transplantation. Stem cells act via two gate theory; direct tissue integration or by paracrine effects [12]. Although the exact mechanisms are not known, some...
of the explored possibilities are: activation of alternative, already existing or dormant neuronal networks, rewiring of new circuits, and neuroplastic reorganizations [11].

This research is an approach to improve our understanding regarding mechanisms underlying functional recovery of cell therapy and the neurobiological correlates of hand movement coupled with growth factor estimation. The primary objective was to study the efficacy of mononuclear stem cells through functional imaging with growth factor estimation after stroke and safety, feasibility being the secondary objective. We present here functional imaging and growth factor estimation at 8 weeks.

Methods

The inclusion criteria are the same as our last published paper from this RCT [9]. Patients diagnosed with ischemic stroke from 3 months to 2 years of index event with the power of hand muscles at least 2, Brunnstrom stage of recovery: II-IV, NIHSS (National Institute of Health stroke scale) of between 4 and 15, conscious/comprehensible were recruited between Nov 2016-Aug 2018. Twenty (n=20) age-matched individuals acted as healthy controls. We screened 40 patients, 10 refused to participate in the trial and 6 had deranged baseline laboratory values, hence twenty-four patients (n=24) were randomized to two groups. Autoimmune disorders, immune-compromised subjects, chronic liver, and renal failure, progressive neurological worsening, neoplasia contraindication to MRI, and pregnancy formed the exclusion. Patients were randomized (computer-assisted) into two groups; one group receiving intravenous MNC and other placebo/ saline infusion. All patients were administered 8 weeks of neuromotor rehabilitation. The groups were referred to as group 1 & group 2 without treatment allocation being disclosed. Patients were screened, educated about stem cells & bone marrow aspiration technique. Written informed consent, complete medical history, examination, and baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, and baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique. Written informed consent, complete medical history, examination, baseline laboratory tests were performed. The patients were examined by a neurologist and neurophysiotherapist for clinical and functional assessment [9,13,14]. The outcome measures were MRC scale, tone (Ashworth), Fuglmeyster score (FM) for upper limb, Brunnstrom stage of stroke recovery, modified Barthel index (mBI) & bone marrow aspiration technique.
+1.0, where +1.0 indicates that all the cortical activity occurred within the ipsilesional ROI and –1.0 indicates that all the cortical activity occurred within the contralesional cortical motor area.

**Results**

**Clinical**

No serious adverse events were reported in the study until the first follow up. The baseline and clinical characteristics of all patients are presented in table 1. To make results readable, we denoted the groups as 1& 2 without the treatments being disclosed (RCT design). There was no significant difference in clinical scores between group 1 and group 2 at 8 weeks in mBI (65.4 versus 63.2; p=0.72), FM(39.4 vs 41;p=0.53), ashworth (1 vs 2; p=0.29) & MRC (3 vs 2; p=0.17) where as pre and post-treatment scores were statistically significant for both groups 1& 2 respectively (p<0.05). For VEGF, the baseline level was 336±78.6 pg/ml in group 1 and 370±91.3 pg/ml in group 2 indicating a relatively similar biomarker level at baseline (95% CI~ 5.6 to 3.2; p=0.067). All patients showed improvement pre and post-therapy(p<0.05), but no statistically significant difference observed between the two groups at 8 weeks (mean 453.5±89.1 vs. 408.4±93.3 pg/ml, 95% CI~13.3–6.7, p=0.67). The median values for VEGF be-

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
<th>P-value</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=10</td>
<td>N=10</td>
<td>N=20</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>8</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Age</td>
<td>48.6 ± 7.1</td>
<td>48.1±9.1</td>
<td></td>
</tr>
<tr>
<td>Avg. time of stroke onset</td>
<td>11.5</td>
<td>10.6</td>
<td></td>
</tr>
</tbody>
</table>

**Risk factors**

- Hypertension: 7 (70%) vs 6 (60%); p=0.15 vs 12
- Diabetes mellitus: 5 (50%) vs 3 (30%); p=0.87 vs 6
- Hypercholesterolemia: 6 (60%) vs 4 (40%); p=0.56 vs 10
- Smoking: 4 (40%) vs 4 (40%); p=0.49 vs 13
- Alcohol consumption: 3 (30%) vs 2 (20%); p=1.0 vs 5
- Tobacco abuse: - vs - vs - 3
- CAD: - vs - vs - 5

**Clinical & imaging parameters**

**Baseline**

- FM: 23.9 vs 21.4; p=0.42
- mBI: 46.7 vs 46.2 vs 0.86
- cluster counts Rt BA 4: 378.1 vs 739.4; p=0.15
- cluster counts Rt BA 6: 688.2 vs 715; p=0.91
- cluster counts Lt BA4: 385.9 vs 697.4; p=0.15
- cluster counts Lt BA 6: 870.7 vs 550.6; p=0.10
- LI BA 4: -0.13 vs -0.15 vs 0.21
- LI BA 6: -0.06 vs -0.21 vs 0.81
- % signal intensity: 0.24 vs 0.47 vs 0.44

**At 8 weeks**

- FM: 39.7 vs 34.1; p=0.53
- mBI: 65.9 vs 61 vs 0.72
- cluster counts Rt BA 4: 537.9 vs 845.5; p=0.15
- cluster counts Rt BA 6: 1235 vs 1177.5; p=0.87
- cluster counts Lt BA4: 712 vs 1260; p=0.15
- cluster counts Lt BA 6: 1795 vs 956.8; p=0.03
- LI BA 4: 0.26 vs 0.24 vs 0.85
- LI BA 6: 0.43 vs 0.21 vs 0.12
- % signal intensity: 0.24 vs 0.29 vs 0.42

Table 1. Baseline and clinical data of patients categorized into groups 1 & 2.
between groups 1 and 2 were also non-significant at 8 weeks (442.1 vs. 400.3 pg/ml, p=0.67). BDNF behaved in a similar path without showing significant changes between groups 1 & 2 (95% CI~ -5.6 to 7.8; p=0.57) although the mean in group 1 was slightly higher than group 2 (32.8 ng/ml vs 27.3 ng/ml, 95% CI~ p=0.57).

**Bold**

We observed that laterality index of ipsilesional BA 4 & 6 was statistically insignificant between both the groups (95% CI~ -0.45 to -0.12; p=0.45 and 95% CI~ -0.33 to -0.17; p=0.06 respectively). In group 1, LI of BA 4 increased from -0.13 to 0.26 (p=0.003) and LI BA6 increased from -0.06 to 0.43 (p=0.001). In group 2, LI BA4 increased from -0.15 to 0.24 and -0.21 to 0.21 for LI BA6 (table 2). It was observed that there was a 59.2% increase in cluster counts of left BA6 and 56.2% increase in right BA6 in group 2. Similarly, the primary motor cortex (BA4) showed an increase in cluster counts in group 1 and 2 with a statistically significant increase in post-treatment (p=0.006). The % signal intensity was nonsignificant between the groups (p=0.43) although it increased from 0.04 to 0.58 in group 1 & 0.04 to 0.36 in group 2. The mean gain in % signal intensity of the motor cortex region was calculated and we observed that group 1 had higher gains than group 2 patients (8.2 vs 5.8, p= 0.67).

**Correlation of growth factors with BOLD parameters**

Serum BDNF correlated well with FM score at 8 weeks in group 1 (r=0.72, p=0.05) as compared to group 2 (r=0.68, p=0.09) (figure 1). VEGF did not show any strong correlation with FM (figure 2) (group 1; r=0.45, p=0.89; group 2; r=0.37, p=0.67); hence we correlated laterality index (LI) of ipsilesional cortex with serum VEGF. Two patients in group 2 had negative LI with a mean VEGF of 430.5 pg/ml, though the correlation line was progressively linear for these patients with positive LI (r=0.53,p=0.12). In group 1, LI showed a positive correlation with serum VEGF in all 10 subjects (r=0.62, p=0.04) with an increasing mean at 8 weeks (figure 3) as compared to group 2 (95% CI~1.4 to 2.3, r=0.58, p=0.56).

**Discussion**

The novelty of the research is to understand the paracrine mechanisms of stem cells through functional imaging and growth factor up regulation. We reviewed Pubmed, Embase, and Scopus sincerely for stroke recovery and delightfully quote a number of cluster counts in the motor cortex post-therapy in both groups which suggests therapy-induced neural plasticity occurring in the brain with cell transplantation and/or exercise regime. Increased BOLD activation was observed in BA6 than BA4 in all patients suggesting the role of BA6 in motor execution, precision, and bimanual hand activation with coordination (figure 4) [20]. To support the hypothesis that chronic stroke patients with less than full recovery are more likely to activate a number of primary, non-primary motor, cingulate and cerebellar regions [21], our results also showed the same trend indicating increased LI of motor cortices (BA 4 & 6) post-treatment in both the groups. The InveST (Intravenous Autologous Bone Marrow Mononuclear Cell Therapy for Ischemic Stroke) trial tested whether an intravenous infusion of autologous bone marrow mononuclear cells between 7 to 30 days (acute to sub-acute) after stroke onset could result in a reduction of the infarct volume and could improve neurological function at day 180 of follow up [22], however, we did not find any change in the lesion volume (data not shown).

The effectiveness of stem cells to enhance functional recovery after stroke has been regularly reported during the last decade in the literature [23]. Another recent phase 2, randomized, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells showed no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83) [24]. In a recent report of a regeneration model of spinal cord injury, the C17.2 murine neural progenitor cell line was grafted into the lesion [6,25]. Several growth factors like NGF, BDNF, and GDNF were known to have released as an observation of axonal sprouting of endogenous cells resulting in outcome measures improvement. Another document suggests that functional improvement of animals treated with stem cells after stroke does not take place on the short term, but takes time.

One of the most fascinating abilities of CNS is to reorganize after any injury. fMRI has provided important insights into the reorganization of the motor cortices after stroke [18,19]. Coupled with cell transplantation, the therapeutics in stroke recovery have been intrigued and well answered by BOLD & DTI. The reported fMRI derived patterns of motor system activation following stroke are variable and their interpretation regarding the recovery process is controversial. We observed an increased number of cluster counts in the motor cortex post-therapy in both groups which suggests therapy-induced neural plasticity occurring in the brain with cell transplantation and/or exercise regime. Increased BOLD activation was observed in BA6 than BA4 in all patients suggesting the role of BA6 in motor execution, precision, and bimanual hand activation with coordination (figure 4) [20]. To support the hypothesis that chronic stroke patients with less than full recovery are more likely to activate a number of primary, non-primary motor, cingulate and cerebellar regions [21], our results also showed the same trend indicating increased LI of motor cortices (BA 4 & 6) post-treatment in both the groups. The InveST (Intravenous Autologous Bone Marrow Mononuclear Cell Therapy for Ischemic Stroke) trial tested whether an intravenous infusion of autologous bone marrow mononuclear cells between 7 to 30 days (acute to sub-acute) after stroke onset could result in a reduction of the infarct volume and could improve neurological function at day 180 of follow up [22], however, we did not find any change in the lesion volume (data not shown).

The effectiveness of stem cells to enhance functional recovery after stroke has been regularly reported during the last decade in the literature [23]. Another recent phase 2, randomized, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells showed no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83) [24]. In a recent report of a regeneration model of spinal cord injury, the C17.2 murine neural progenitor cell line was grafted into the lesion [6,25]. Several growth factors like NGF, BDNF, and GDNF were known to have released as an observation of axonal sprouting of endogenous cells resulting in outcome measures improvement. Another document suggests that functional improvement of animals treated with stem cells after stroke does not take place on the short term, but takes time.
<table>
<thead>
<tr>
<th>S.No</th>
<th>Age/sex</th>
<th>Time after stroke</th>
<th>Task</th>
<th>Baseline</th>
<th>8 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BA4 cluster counts</td>
<td>LI BA4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>1</td>
<td>55/M</td>
<td>12</td>
<td>LFM</td>
<td>543</td>
<td>786</td>
</tr>
<tr>
<td>2</td>
<td>52/M</td>
<td>9</td>
<td>RFM</td>
<td>1575</td>
<td>320</td>
</tr>
<tr>
<td>3</td>
<td>45/F</td>
<td>5</td>
<td>LFM</td>
<td>56</td>
<td>89</td>
</tr>
<tr>
<td>4</td>
<td>36/M</td>
<td>14</td>
<td>RFM</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>57/M</td>
<td>12</td>
<td>LFM</td>
<td>23</td>
<td>56</td>
</tr>
<tr>
<td>6</td>
<td>60/M</td>
<td>10</td>
<td>RFM</td>
<td>456</td>
<td>673</td>
</tr>
<tr>
<td>7</td>
<td>53/M</td>
<td>11</td>
<td>RFM</td>
<td>387</td>
<td>126</td>
</tr>
<tr>
<td>8</td>
<td>46/M</td>
<td>7</td>
<td>LFM</td>
<td>35</td>
<td>79</td>
</tr>
<tr>
<td>9</td>
<td>40/M</td>
<td>8</td>
<td>RFM</td>
<td>431</td>
<td>674</td>
</tr>
<tr>
<td>10</td>
<td>42/F</td>
<td>9</td>
<td>RFM</td>
<td>275</td>
<td>1056</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td>378.1</td>
<td>385.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S.No</th>
<th>Age/sex</th>
<th>Time after stroke</th>
<th>Task</th>
<th>Baseline</th>
<th>8 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BA4 cluster counts</td>
<td>LI BA4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>1</td>
<td>33/M</td>
<td>5</td>
<td>LFM</td>
<td>269</td>
<td>567</td>
</tr>
<tr>
<td>2</td>
<td>45/M</td>
<td>9</td>
<td>RFM</td>
<td>1179</td>
<td>890</td>
</tr>
<tr>
<td>3</td>
<td>58/M</td>
<td>15</td>
<td>LFM</td>
<td>23</td>
<td>78</td>
</tr>
<tr>
<td>4</td>
<td>56/M</td>
<td>9</td>
<td>RFM</td>
<td>538</td>
<td>1085</td>
</tr>
<tr>
<td>5</td>
<td>42/M</td>
<td>18</td>
<td>LFM</td>
<td>56</td>
<td>78</td>
</tr>
<tr>
<td>6</td>
<td>60/M</td>
<td>8</td>
<td>RFM</td>
<td>564</td>
<td>764</td>
</tr>
<tr>
<td>7</td>
<td>61/M</td>
<td>18</td>
<td>RFM</td>
<td>1456</td>
<td>1289</td>
</tr>
<tr>
<td>8</td>
<td>60/M</td>
<td>6</td>
<td>LFM</td>
<td>1349</td>
<td>745</td>
</tr>
<tr>
<td>9</td>
<td>47/F</td>
<td>7</td>
<td>RFM</td>
<td>325</td>
<td>433</td>
</tr>
<tr>
<td>10</td>
<td>49/M</td>
<td>10</td>
<td>RFM</td>
<td>1635</td>
<td>865</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td>739.4</td>
<td>679.4</td>
</tr>
</tbody>
</table>

Table 2. BOLD activation pattern depicting cluster counts and Laterality index (LI) of patients in group 1 & group 2.

before the therapeutic effect becomes detectable. This finding is in agreement with previously published works that depict a delayed action of implanted stem cells [26] which justifies our inclusion criteria of patients being selected when the apparent spontaneous recovery after stroke was over and before any scarring occurs in the brain (3mo-2 yrs). Our last paper postulated that the paracrine effects of stem cells levy over cell replacement and this paper is a further exploration of functional recovery post stem cell transplantation after stroke and correlation of growth factors with BOLD imaging [9].

Given the evidence linking BDNF and brain plasticity, research advancements have been made to understand the response of BDNF levels to physical exercise training and its beneficial effects on learning [27]. Thus, using neuro rehabilitative training as an intervention to optimize neuro plasticity and recovery in patients post-stroke has gained considerable interest [28]. Low serum BDNF was found to be associated with poor long-term outcome after stroke [29]. However, the relationship of serum BDNF with the short-term outcome is controversial; one study reported a correlation of low BDNF at 3 months with FIM motor subscore at discharge (r=0.17, p=0.001) and FIM total score at discharge (r=0.15, p=0.004) [30]. However, in our study, we observed that serum BDNF had a positive correlation with fuglmeyer (FM) motor score for upper limb (r=0.72, p=0.05) in group 1as compared to group 2 (figure 1). The task performance was better in both groups at 8 weeks as observed through BOLD imaging with an increase in cluster counts in BA 4 & 6 (p<0.05). The % signal intensity was non significant between the groups (p=0.43) although it increased from 0.04 to 0.58in group.
Figure 1. Correlation of BDNF with FM scores at 8 weeks in both groups.

Figure 2. Correlation of VEGF and FM score in both groups at 8 weeks.
Figure 3. Correlation of serum VEGF & laterality index (LI) of BA 4 at 8 weeks.

Figure 4. BOLD imaging of group 1 subjects: a) Pre treatment B) post treatment
Signal intensity is a marker of signal strength of neurons when combined with oxygen to form oxyhemoglobin, an increased signal intensity leads to an enhanced neurovascular coupling consequently neuronal O2 being used for movement [31,32]. Exercise therapy leads to activation of primary motor cortices sensorimotor cortex, premotor cortex, SMA, cingulate, cerebellum, basal ganglia is a unanimous observation, also depicted from our results [33]. Regional blood flow is enhanced by aerobic training exerting its function through neurovascular remodeling mainly through serum VEGF. It did not show a strong correlation with clinical scores in our patients hence we correlated laterality index (LI) of the ipsilesional cortex with serum VEGF in both groups [34]. Also it is known that the compound gets up regulated in the acute phase of stroke [35].

Our a priori intention was to correlate changes in brain activation patterns to changes in performance due to neurorestorative therapies, and not time after stroke and we observed that functional changes in a stroke patient are well correlated with neurotrophic growth hormones and imaging especially BDNF than VEGF [36]. Use of imaging in clinical trials is strongly encouraged to provide as much information as possible to assess vascular/structural lesions, infarct size, cell viability, location, the success, safety of implantation. Imaging should also be used to monitor safety and recovery and, when possible, to investigate mechanisms of action and provide information on surrogate markers of treatment effect. Imaging measures might also be useful to help stratify patients at baseline [37].

To summarize, our interim analysis of a randomized controlled trial suggest that functional recovery post cell transplantation occurs as both the groups performed well on imaging and laboratory parameters. The increase in cluster counts of primary motor cortex along with the upsurge of neurotrophic hormones VEGF & BDNF in both groups indicates therapy-induced reorganization [38,39]. The data is still under evaluation, the study groups will be revealed once the trial is over and a better understanding of the results will be published.

Conclusion

Autologous bone marrow-derived mononuclear stem cells is safe and feasible in chronic stroke. There is a probable positive correlation between the BOLD-signal size, activation of primary & supplementary motor area, and good functional status from sub acute to the chronic period of stroke. Stem cells and neural rehabilitation lead to an increase in neurotrophic hormones and functional reorganization in motor cortices.

Acknowledgment

AB & MVP designed the manuscript. SSK laid the BOLD protocol and fMRI data analysis. SV, SS, NK helped in growth factor correlation, RB & SM helped in revision.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The research was sanctioned by the Department of Science and Technology, DST, India, New Delhi.
# References


J Scholar Publishers

J Stem Cell Rep 2020 | Vol 2: 101


Submit your manuscript to a JScholar journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Better discount for your subsequent articles

Submit your manuscript at http://www.jscholaronline.org/submit-manuscript.php